Home / Stock ratings / EW
Stock rating · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Edwards Lifesciences Corp (EW) Stock Rating & Analysis
As of November 20, 2026, MELANY rates Edwards Lifesciences Corp 58 out of 100 (Very Promising). Its highest factor score is price momentum at 75, and its lowest is valuation at 35.
EW · composite score
About Edwards Lifesciences Corp
Edwards Lifesciences, spun off from Baxter International in 2000, designs, manufactures, and markets medical devices and equipment for advanced structural heart disease. It is a leader across key products including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. About 60% of its total sales come from outside the US.
Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).
Why EW scores 58/100
EW's 8 factor scores run from 35 to 75, and 5 of them sit above its composite of 58. Here is how EW breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 30.1x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 78%
Direction and relative strength of the recent share-price trend.
- Price +10.4% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How EW compares
As of November 20, 2026, Edwards Lifesciences Corp is tied for 2nd of the 3 companies with a MELANY rating page in its SEC industry group (Orthopedic, Prosthetic & Surgical Appliances & Supplies), where the average score is 59.
Key risks for EW
- Performance partly driven by Healthcare sector, rotation away from this theme would hurt
Sector and theme context
Edwards Lifesciences Corp sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds EW's momentum and catalyst factors above.
EW trade plan (Pro)
MELANY has a full position plan for Edwards Lifesciences Corp: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates EW
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Edwards Lifesciences Corp's 58/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about EW
Is Edwards Lifesciences Corp (EW) a buy?
As of 2026-11-20, MELANY rated Edwards Lifesciences Corp Very Promising with a composite score of 58/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
How does EW rank against similar companies?
As of November 20, 2026, Edwards Lifesciences Corp is tied for 2nd of the 3 companies with a MELANY rating page in its SEC industry group (Orthopedic, Prosthetic & Surgical Appliances & Supplies), where the average score is 59. Among the other names in the group, the highest scores belong to ZBH (61) and ISRG (58).
Should I buy Edwards Lifesciences Corp stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Edwards Lifesciences Corp (EW) Very Promising with a composite of 58/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the EW stock price forecast?
MELANY does not publish price targets or forecasts for EW. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 58/100 across eight factors for Edwards Lifesciences Corp, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for EW as of 2026-11-20: its analyst sentiment factor is 69/100, and its price momentum factor is 75/100.
Is EW stock overvalued or undervalued?
MELANY's valuation factor currently reads 35/100 for Edwards Lifesciences Corp, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives EW's read.
What price should I buy EW at?
Rather than chasing the current price, MELANY computes a smart entry zone for EW: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying EW stock?
The top risks MELANY currently flags for Edwards Lifesciences Corp: Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Edwards Lifesciences Corp a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 72/100 for Edwards Lifesciences Corp, and earnings track record, at 65/100. The 58/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will EW stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 75/100 for EW right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this EW rating?
The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores EW as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, EW included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.